X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Novartis and University of Oxford to establish AI based Drug Development Alliance

Content Team by Content Team
22nd January 2019
in Drug Development, Manufacturing, News, Packaging & Logistic
Novartis and University of Oxford to establish AI based Drug Development Alliance

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Novartis has partnered with the University of Oxford’s Big Data Institute (BDI) to boost drug development using artificial intelligence (AI) and advanced analytics.

The partners intend to focus on analysis, combination and interpretation of datasets to identify markers that allow early prediction of patient responses to therapies for inflammatory diseases, including psoriasis.

As part of the alliance, relevant clinical trial data from Novartis will be combined with data from nearly five million patients from the UK and other international partner organisations.

The prediction of patient responses to medicines is expected to be enabled through BDI’s statistical machine learning technology and data analysis, along with Novartis’s clinical specialism and trial data.

Novartis and BDI also plan to develop an AI technology and IT environment to identify patterns in data.

In addition, the partners will work on the characteristics of select diseases to gain a better insight into disease progression and commonalities between diseases.

Novartis chief medical officer and global drug development head John Tsai said: “Our work with the Big Data Institute will enable us to combine different types of data such as clinical, imaging and genomics, and use advanced analytical capabilities to change how we look at diseases and discover new insights.

“This has the potential to transform how we design and conduct our clinical development programmes of the future.”

Initially, the partners will focus on two of Novartis’s global drug development (GDD) organisation programmes to further understand multiple sclerosis (MS), dermatology and rheumatology.

Big Data Institute director Gil McVean said: “Our collaboration with Novartis will enable both organisations to transform the scale and efficiency of clinical research at an unprecedented rate through the sharing of data, technology, and advanced analytics expertise.

“The BDI enables people and projects to span traditional boundaries and scientific disciplines and leverage technological innovation for the benefit of patients.”

The collaboration covers knowledge exchange and access to a network of scientific talent. It will also leverage the expertise of various other partners.

 

 

Previous Post

NeuroBo Pharmaceuticals to Initiate Phase III Clinical Trial of NB-01 in Adult Patients with Diabetic Neuropathic Pain

Next Post

TrakCel and Quick partner to provide Digital Supply Chain IT solution for Cell and Gene Therapies

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
TrakCel and Quick partner to provide Digital Supply Chain IT solution for Cell and Gene Therapies

TrakCel and Quick partner to provide Digital Supply Chain IT solution for Cell and Gene Therapies

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In